Advances of diagnosis and therapy for desmoplastic small round cell tumor

doi:10.3760/cma.j.issn.1673-422X.2018.06.015

Abstract

Abstract: Desmoplastic small round cell tumor (DSRCT) is a rare and high malignant soft tissue tumor with very poor prognosis. It usually occurs in the abdominopelvic cavity of adolescents and young males. DSRCT is prone to occur distant metastasis, mainly in the liver and lung. The histopathological manifestation is featured with nests of small round blue cells separated by desmoplastic stroma. DSRCT can coexpress epithelial, neural and mesenchymal markers. The molecular characteristic of DSRCT is the production of EWS-WT1 fusion protein via the translocation of chromosome t (11; 22) (p13; q12). Treatments of DSRCT include radical resection or cytoreductive surgery, high intensity systemic chemotherapy, local radiotherapy and hyperthermic intraperitoneal chemotherapy.

Key words: Diagnosis, Therapy, Desmoplastic small round cell tumor

Chen Huoguang, Wang Hongbiao, Lin Yingcheng. Advances of diagnosis and therapy for desmoplastic small round cell tumor[J]. Journal of International Oncology, 2018, 45(6): 379-382.

References

［1］ Lettieri CK, GarciaFilion P, Hingorani P. Incidence and outcomes of desmoplastic small round cell tumor: results from the surveillance, epidemiology, and end results database［J］. J Cancer Epidemiol, 2014, 2014: 680126. DOI: 10.1155/2014/680126. ［2］ Bent MA, Padilla BE, Goldsby RE, et al. Clinical characteristics and outcomes of pediatric patients with desmoplastic small round cell tumor［J］. Rare Tumors, 2016, 8(1): 6145. DOI: 10.4081/rt.2016.6145. ［3］ Angarita FA, Hassan S, Cannell AJ, et al. Clinical features and outcomes of 20 patients with abdominopelvic desmoplastic small round cell tumor［J］. Eur J Surg Oncol, 2017, 43(2): 423-431. DOI: 10.1016/j.ejso.2016.08.017. ［4］ Shen XZ, Zhao JG, Wu JJ, et al. Clinical and computed tomography features of adult abdominopelvic desmoplastic small round cell tumor［J］. World J Gastroenterol, 2014, 20(17): 5157-5164. DOI: 10.3748/wjg.v20.i17.5157. ［5］ HayesJordan A, LaQuaglia MP, Modak S. Management of desmoplastic small round cell tumor［J］. Semin Pediatr Surg, 2016, 25(5): 299304. DOI: 10.1053/j.sempedsurg.2016.09.005. ［6］ Negri T, Brich S, Bozzi F, et al. New transcriptionalbased insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs)［J］. Oncotarget, 2017, 8(20): 32492-32504. DOI: 10.18632/oncotarget.16477. ［7］ Honoré C, Atallah V, Mir O, et al. Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: is there a benefit for HIPEC after macroscopically complete cytoreductive surgery?［J］. PLoS One, 2017, 12(2): e0171639. DOI: 10.1371/journal.pone.0171639. ［8］ Zhang S, Zhang Y, Yu YH, et al. Results of multimodal treatment for desmoplastic small round cell tumor of the abdomen and pelvis［J］. Int J Clin Exp Med, 2015, 8(6): 96589666. ［9］ HayesJordan A, Green H, Lin H, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases［J］. Ann Surg Oncol, 2015, 22(5): 1726-1732. DOI: 10.1245/s10434-014-4289-y. ［10］ Wong HH, Hatcher HM, Benson C, et al. Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature［J］. Clin Sarcoma Res, 2013, 3(1): 14. DOI: 10.1186/20453329-3-14. ［11］ Bulbul A, Fahy BN, Xiu J, et al. Desmoplastic small round blue cell tumor: a review of treatment and potential therapeutic genomic alterations［J］. Sarcoma, 2017, 2017: 1278268. DOI: 10.1155/2017/1278268. ［12］ HayesJordan A, Green HL, Lin H, et al. Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor［J］. Ann Surg Oncol, 2014, 21(1): 220-224. DOI: 10.1245/s10434-013-3269-y. ［13］ Atallah V, Honore C, Orbach D, et al. Role of adjuvant radiation therapy after surgery for abdominal desmoplastic small round cell tumors［J］. Int J Radiat Oncol Biol Phys, 2016, 95(4): 12441253. DOI: 10.1016/j.ijrobp.2016.02.046. ［14］ Desai NB, Stein NF, LaQuaglia MP, et al. Reduced toxicity with intensity modulated radiation therapy (IMRT) for desmoplastic small round cell tumor (DSRCT): an update on the whole abdominopelvic radiation therapy (WAPRT) experience［J］. Int J Radiat Oncol Biol Phys, 2013, 85(1): e67-72. DOI: 10.1016/j.ijrobp.2012.09.005. ［15］ Frezza AM, Benson C, Judson IR, et al. Pazopanib in advanced desmoplastic small round cell tumours: a multiinstitutional experience［J］. Clin Sarcoma Res, 2014, 4: 7. DOI: 10.1186/2045-3329-4-7. ［16］ Menegaz BA, Cuglievan B, Benson J, et al. Clinical activity of pazopanib in patients with advanced desmoplastic small round cell tumor［J］. Oncologist, 2018, 23(3): 360-366. DOI: 10.1634/theoncologist.20170408. ［17］ Italiano A, Kind M, Cioffi A, et al. Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series［J］. Target Oncol, 2013, 8(3): 211-213. DOI: 10.1007/s1152301202518. ［18］ De Sanctis R, Bertuzzi A, Bisogno G, et al. Imatinib mesylate in desmoplastic small round cell tumors［J］. Future Oncol, 2017, 13(14): 1233-1237. DOI: 10.2217/fon-2016-0305. ［19］ Tap WD, Demetri G, Barnette P, et al. Phase Ⅱ study of ganitumab, a fully human antitype1 insulinlike growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors［J］. J Clin Oncol, 2012, 30(15): 1849-1856. DOI: 10.1200/JCO.2011.37.2359. ［20］ Subbiah V, Brown RE, Jiang Y, et al. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing′s sarcoma (EWS/FLI1) and Wilms′ tumor (WT1)［J］. PLoS One, 2013, 8(7): e68985. DOI: 10.1371/journal.pone.0068985. ［21］ Tarek N, HayesJordan A, Salvador L, et al. Recurrent desmoplastic small round cell tumor responding to an mTOR inhibitor containing regimen［J］. Pediatr Blood Cancer, 2018, 65(1). DOI: 10.1002/pbc.26768.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[6]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[7]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[8]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[9]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[10]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[11]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng. Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor [J]. Journal of International Oncology, 2024, 51(5): 298-302.
[12]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[13]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[14]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[15]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.